Chiasma Reports Fourth Quarter and Year End 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer
March 15, 2016 7:48 AM EDTChiasma (NASDAQ: CHMA) reported 4Q15/FY2015, ending the quarter with $148.8M in cash, which Oppenheimer analyst, Christopher Marai, believes is sufficient to fund operations through profitability, assuming US approval. The company also announced total aggregate R&D and SG&A including stock-based comp of $80-88M. No change to Outperform rating or $43 PT.
The Phase-3 "MPOWERED" trial for an EU regulatory submission initiated. EU submission expected 2019. The trial will evaluate the non-inferiority (20% margin) of octreotide capsules to injectable... More
